---
title: "MetaVia announces $10.0 million private placement priced at the market"
url: "https://aibio.space/news/metavia-announces-10-0-million-private-placement-priced-market/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-05-14"
section: "Financings"
tickers: "NASDAQ:MTVA"
source: "https://www.sec.gov/Archives/edgar/data/1638287/000110465925048210/tm259573d4_ex99-1.htm"
summary: "Investors are buying 9,479,345 shares at $0.71 and 4,605,162 pre-funded warrants. Proceeds go mainly to development of obesity candidate DA-1726."
---

By the aibio.space news desk.

Sources

- [MetaVia Inc. 8-K (2025-05-14)](https://www.sec.gov/Archives/edgar/data/1638287/000110465925048210/tm259573d4_ex99-1.htm)

[MTVA](https://aibio.space/companies/metavia/)

2025-05-14

# MetaVia announces $10.0 million private placement priced at the market

Tickers [MTVA](https://aibio.space/companies/metavia/)

Investors are buying 9,479,345 shares at $0.71 and 4,605,162 pre-funded warrants. Proceeds go mainly to development of obesity candidate DA-1726.

## Key facts

- **Company**: MetaVia Inc. (NASDAQ: MTVA)

- **News type**: Financings

- **Primary source**: [MetaVia Inc. 8-K (2025-05-14)](https://www.sec.gov/Archives/edgar/data/1638287/000110465925048210/tm259573d4_ex99-1.htm)

*The lower Manhattan skyline. CC0, via rawpixel. The picture shows the field, not the companies named.*

MetaVia Inc. (Nasdaq: [MTVA](https://aibio.space/companies/metavia/)) announced on May 9, 2025 a private placement that it estimates will bring gross proceeds of approximately $10.0 million, before placement agent fees and other expenses.

According to the [press release](https://www.sec.gov/Archives/edgar/data/1638287/000110465925048210/tm259573d4_ex99-1.htm) filed with an 8-K, investors agreed to buy 9,479,345 shares of common stock at $0.71 per share. They also agreed to buy 4,605,162 pre-funded warrants at $0.709 each. A pre-funded warrant is mostly paid for up front. These carry an exercise price of $0.001 and become exercisable once stockholders approve the underlying shares.

The deal was priced at the market under Nasdaq rules. Closing was expected on or about May 12, 2025. The securities are being sold to institutional accredited investors under an exemption from SEC registration. MetaVia agreed to file a resale registration statement and to seek stockholder approval for the shares underlying the pre-funded warrants. Ladenburg Thalmann & Co. Inc. was exclusive placement agent.

The Cambridge, Massachusetts company plans to use the net proceeds for working capital and corporate purposes, including continued clinical development of DA-1726 for obesity.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

MTVA

MetaVia Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/metavia-announces-10-0-million-private-placement-priced-market/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MetaVia announces $10.0 million private placement priced at the market", 2025-05-14, https://aibio.space/news/metavia-announces-10-0-million-private-placement-priced-market/